Document is current
Any future updates will be listed below
-
Authors
Juarez-Vignon Whaley, Juan Jose
Afkhami, Michelle
Onyshchenko, Mykola
Massarelli, Erminia
Sampath, Sagus
Amini, Arya
Bell, Diana
Villaflor, Victoria M.
-
Funding
Funding for this research was provided by:
City of Hope
- License Information
-
More Information
Article History
Accepted: 24 April 2023
First Online: 15 June 2023
Compliance with Ethical Standards
:
: All authors reported any conflicts of interest, if any, in their respective ICMJE form. None of the reported conflicts of interests are associated with the current manuscript. Juan Jose Juarez-Vignon Whaley, Michelle Afkhami, Mykola Onyshckenko, Sagus Sampath, Arya Amini, and Diana Bell have no potential conflicts of interest to report. Erminia Massarelli: Honoraria — AstraZeneca, Merck; Consulting/Advisory Role — Genentech/Roche, Merck, Lilly, Jansen Scientific Affairs, Sanofi, Bristol Myers Squibb Foundation, Daiichi Sankyo Co, Abbvie; Speakers´ Bureau: Merck, AstraZeneca, Takeda, Lilly, Mirati Therapeutics; Research Funding: Merch, AstraZeneca, Pfizer, Tessa Therapeutics, Bristol-Myers Squibb, GlaxoSmithKline, Genentech. Travel, Acommodotions, Expenses: Bristol-Myers Squibb, Merck, Genentech/Roche, Pfizer, AstraZeneca. Victoria M. Villaflor: Research Funding — Takeda; Stock Ownership — Johnson and Johnson; Advisory Board — Astra Zeneca.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
